Erasca

Erasca’s pipeline includes modality-agnostic programs targeting the RAS/MAPK pathway through upstream/downstream nodes, direct RAS targeting, and escape route inhibition.

Proceeds of financing will fuel corporate development efforts and further buildout of artificial intelligence platform to accelerate drug discovery in bold mission to erase cancer SAN DIEGO, Mar. 5, 2019 — Erasca, a company dedicated to advancing exceptional scientific approaches to erase

Company, co-founded by physician-turned-venturepreneur Dr. Jonathan E. Lim, is targeting undisclosed biological drivers of cancer SAN DIEGO, Dec. 18, 2018 — Erasca, a company dedicated to advancing exceptional scientific approaches to erase cancer, has completed a $42 million Series A financing

Erasca picks up $42M to target biological drivers of cancer December 18, 2018 « back to news page

SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 40 th annual

Clinical Trial Manager/Sr Clinical Trial Manager San Diego, CA or remote apply Erasca is a clinical-stage precision oncology company focused on discovering, developing and commercializing medicines for the benefit of patients with cancer. Our programs take novel approaches to shutting down one of cancer’s most commonly mutated signaling cascades, the RAS/MAPK pathway, which affects approximately 5.5 million […]

Erasca seeks an executive director or vice president of regulatory affairs for roles in San Diego, South San Francisco, or remotely.

Erasca was co-founded by pioneers in precision oncology and RAS targeting to develop therapies that silence the RAS/MAPK pathway for cancer treatment.

Erasca is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for RAS- and MAPK pathway-driven cancers.

In May 2021, Erasca established the Erasca Foundation, a 501(c)(3) private foundation, funded by a donation of 1,093,557 shares of common stock.

Erasca Ventures, Erasca’s wholly-owned subsidiary, invests in early-stage biotechnology companies aligned with Erasca’s mission and strategy.

Erasca targets the RAS/MAPK pathway, which affects approximately 5.5 million lives annually, with a pipeline addressing the pathway at multiple points.

Erasca’s privacy policy outlines how the company collects, uses, and safeguards personal information.